SCHEMBL19743111

SCHEMBL19743111

O=C(O)CCC(NC(=O)NC(CCCCNC(=O)Cc1ccc(I)cc1)C(=O)O)C(=O)O

nearest known ligand 0.72

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 18/20 0.72
▸ ALB P02768 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19743110 1.00 FOLH1 (0.72) FOLH1ALB
SCHEMBL19748291 0.92 FOLH1 (0.69) FOLH1ALB
SCHEMBL19743078 0.90 FOLH1 (0.71) FOLH1ALB
SCHEMBL19743077 0.90 FOLH1 (0.71) FOLH1ALB
SCHEMBL19360806 0.90 FOLH1 (0.70) FOLH1
SCHEMBL19743080 0.89 ALB (0.77) FOLH1ALB
SCHEMBL19743082 0.89 ALB (0.77) FOLH1ALB
SCHEMBL19754087 0.89 FOLH1 (0.67) FOLH1ALB
SCHEMBL19743100 0.86 ALB (0.72) FOLH1ALB
SCHEMBL19743101 0.86 ALB (0.72) FOLH1ALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091008-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL CORNELL UNIVERSITY (US) 2026-04-02 — — US disclosed
EP-4520745-A2 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL Cornell University (US) 2025-03-12 — — EP disclosed
EP-3474903-B1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL UNIV CORNELL (US) 2025-01-22 — — EP disclosed
US-10716772-B2 Double targeted constructs to affect tumor kill CORNELL UNIVERSITY (US) 2020-07-21 — — US disclosed
US-20190142770-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL CORNELL UNIVERSITY 2019-05-16 — — US disclosed
US-10179117-B2 Double targeted constructs to affect tumor kill CORNELL UNIVERSITY (US) 2019-01-15 — — US disclosed
US-20170368005-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL CORNELL UNIVERSITY 2017-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091008-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL PSMA2, CD47, KLK3 FOLH1 5/4885ALB 1858/4885
US-10716772-B2 Double targeted constructs to affect tumor kill PSMA2, FOLH1, KLK3 FOLH1 2/4885ALB 1812/4885
US-20170368005-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL PSMA2, FOLH1, KLK3 FOLH1 2/4885ALB 1812/4885
US-20190142770-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL PSMA2, FOLH1, KLK3 FOLH1 2/4885ALB 1812/4885
US-10179117-B2 Double targeted constructs to affect tumor kill PSMA2, FOLH1, KLK3 FOLH1 2/4885ALB 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback